Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?

Pharmacology and Therapeutics

Volumn 140, Issue 1, 2013, Pages 34-52

  Harrison, Ian F ^a   Dexter, David T ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Histone deacetylase; Histone deacetylase inhibitor; Neurodegeneration Epigenetics; Neuroprotection; Parkinson's disease

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ABEXINOSTAT; APICIDIN; APOMORPHINE; BELINOSTAT; BUTYRIC ACID; CYCLOPEPTIDE; DACINOSTAT; DNA; ENTACAPONE; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NICOTINAMIDE; OXAMFLATIN; PANOBINOSTAT; PERGOLIDE; PHENYLBUTYRATE; ROMIDEPSIN; SIRTUIN; SURAMIN; TACEDINALINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

AMYGDALOID NUCLEUS; ARTICLE; BRAIN DEPTH STIMULATION; CELL DEATH; CHOROID PLEXUS; CLINICAL FEATURE; DNA METHYLATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; HIPPOCAMPUS; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PROCESSING; PUTAMEN; QUALITY OF LIFE; SUBSTITUTION THERAPY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; 3,4-DIHYDROXYPHENYLACETIC ACID; 3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE; 6-HYDROXYDOPAMINE; 6-OHDA; AC; AC-LYS; ACETYL; ACETYL-LYSINE; AD; ALS; ALZHEIMER'S DISEASE; AMYLOTROPHIC LATERAL SCLEROSIS; BBB; BDNF; BLOOD BRAIN BARRIER; BRAIN DERIVED NEUROTROPHIC FACTOR; CBP; DA; DEOXYRIBONUCLEIC ACID; DNA; DNA METHYLTRANFERASES; DNMT; DOPAC; DOPAMINE; EPIGENETICS; FDA; FOOD AND DRUG ADMINISTRATION; GABA; GCN5-RELATED ACETYLTRANSFERASES; GDNF; GLIAL DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3; GNAT; GSK-3; HAT; HD; HDAC; HDACI; HDM; HEAT SHOCK PROTEIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASES; HISTONE METHYL-TRANSFERASES; HMT; HOMOVANILLIC ACID; HPLC; HSP; HUNTINGTON'S DISEASE; HVA; LIPOPOLYSACCHARIDE; LPS; LSD; LYS; LYSINE; LYSINE-SPECIFIC HISTONE DEMETHYLASE; MAO; ME; MECP2; METHYL; METHYL-CPG BINDING PROTEIN 2; MONOAMINE OXIDASE; MOZ YBF2/SAS3 SAS2 AND TIP60; MPP+; MPTP; MTT; MYST; NAD+; NEURODEGENERATION; NEUROPROTECTION; NICOTINAMIDE ADENINE DINUCLEOTIDE; P300/CREB BINDING PROTEIN; PARKINSON'S DISEASE; PD; PE; PHYCOERYTHRIN; QRT-PCR; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; S-ADENOSYL-HOMOCYSTEINE; S-ADENOSYL-METHIONINE; SAH; SAHA; SAM; SCFA; SHORT CHAIN FATTY ACID; SILENT INFORMATION REGULATOR 2; SIR2; SNPC; SOD; SUBEROYLANILIDE HYDROXAMIC ACID; SUBSTANTIA NIGRA PARS COMPACTA; SUPEROXIDE DISMUTASE; TH; TRICHOSTATIN A; TSA; TYROSINE HYDROXYLASE; Α-SYNUCLEIN; ΑSYN; Γ-AMINOBUTYRIC ACID;

ANIMALS; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PARKINSON DISEASE;

EID: 84883788666     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.05.010     Document Type: Review

References (183)

1. T. Abel, and R.S. Zukin Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders Curr Opin Pharmacol 8 2008 57 64
2. V.G. Allfrey, R. Faulkner, and A.E. Mirsky Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis Proc Natl Acad Sci USA 51 5 1964 786 794
3. D.W. Anderson, K.A. Bradbury, and J.S. Schneider Neuroprotection in Parkinson models varies with toxin administration protocol Eur J Neurosci 24 2006 3174 3182
4. D.W. Anderson, K.A. Bradbury, and J.S. Schneider Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism Eur J Neurosci 28 2008 610 617
5. C.H. Arrowsmith, C. Bountra, P.V. Fish, K. Lee, and M. Schapira Epigenetic protein families: A new frontier for drug discovery Nat Rev Drug Discov 11 2012 384 400
6. J.L. Avalos, K.M. Bever, and C. Wolberger Mechanism of sirtuin inhibition by nicotinamide: Altering the NAD + cosubstrate specificity of a Sir2 enzyme Mol Cell 17 2005 855 868
7. I.A. Ayoub, E. Jian Lee, C.S. Ogilvy, M. Flint Beal, and K.I. Maynard Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats Neurosci Lett 259 1999 21 24
8. M.F. Beal Bioenergetic approaches for neuroprotection in Parkinson's disease Ann Neurol 53 2003 S39 S48
9. S. Berg, B. Serabe, A. Aleksic, L. Bomgaars, L. McGuffey, and R. Dauser Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate Cancer Chemother Pharmacol 47 5 2001 385 390
10. B.E. Bernstein, A. Meissner, and E.S. Lander The mammalian epigenome Cell 128 2007 669 681
11. J.M. Birrell, and V.J. Brown Medial frontal cortex mediates perceptual attentional set shifting in the rat J Neurosci 20 2000 4320 4324
12. G. Blander, and L. Guarente The Sir2 family of protein deacetylases Annu Rev Biochem 73 2004 417 435
13. R.A. Bodner, T.F. Outeiro, S. Altmann, M.M. Maxwell, S.H. Cho, and B.T. Hyman Pharmacological promotion of inclusion formation: A therapeutic approach for Huntington's and Parkinson's diseases Proc Natl Acad Sci USA 103 2006 4246 4251
14. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 2006 769 784
15. H. Braak, K.D. Tredici, U. Rüb, R.A.I. de Vos, E.N.H. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211
16. R.S. Broide, J.M. Redwine, N. Aftahi, W. Young, F.E. Bloom, and C.J. Winrow Distribution of histone deacetylases 1-11 in the rat brain J Mol Neurosci 31 2007 47 58
17. K. Buck, and B. Ferger l-DOPA-induced dyskinesia in Parkinson's disease: A drug discovery perspective Drug Discov Today 15 2010 867 875
18. S. Burridge Target watch: Drugging the epigenome Nat Rev Drug Discov 12 2013 92 93
19. R. Butler, and G.P. Bates Histone deacetylase inhibitors as therapeutics for polyglutamine disorders Nat Rev Neurosci 7 2006 784 796
20. N. Carey, and N.B. La Thangue Histone deacetylase inhibitors: Gathering pace Curr Opin Pharmacol 6 2006 369 375
21. A.A. Castro, K. Ghisoni, A. Latini, J. Quevedo, C.I. Tasca, and R.D.S. Prediger Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) rat model of Parkinson's disease Behav Brain Res 229 1 2012 208 215
22. K.R. Chaudhuri, and A.H.V. Schapira Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment Lancet Neurol 8 2009 464 474
23. P.S. Chen, G.S. Peng, G. Li, S. Yang, X. Wu, and C.C. Wang Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes Mol Psychiatry 11 2006 1116 1125
24. P.S. Chen, C.C. Wang, C.D. Bortner, G.S. Peng, X. Wu, and H. Pang Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity Neuroscience 149 2007 203 212
25. S.H. Chen, H.M. Wu, B. Ossola, N. Schendzielorz, B.C. Wilson, and C.H. Chu Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage Br J Pharmacol 165 2012 494 505
26. D.-M. Chuang, Y. Leng, Z. Marinova, H.-J. Kim, and C.-T. Chiu Multiple roles of HDAC inhibition in neurodegenerative conditions Trends Neurosci 32 2009 591 601
27. C.A. da Costa, K. Ancolio, and F. Checler Wild-type but not Parkinson's disease-related Ala-53 → Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli J Biol Chem 275 2000 24065 24069
28. C.A. da Costa, E. Masliah, and F. Checler β-Synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: Cross-talk with α-synuclein and implication for Parkinson's disease J Biol Chem 278 2003 37330 37335
29. S.J. Darkin-Rattray, A.M. Gurnett, R.W. Myers, P.M. Dulski, T.M. Crumley, and J.J. Allocco Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase Proc Natl Acad Sci 93 1996 13143 13147
30. P.K. Dash, S.A. Orsi, M. Zhang, R.J. Grill, S. Pati, and J. Zhao Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats PLoS One 5 2010 e11383
31. L.M.L. de Lau, and M.M.B. Breteler Epidemiology of Parkinson's disease Lancet Neurol 5 2006 525 535
32. A.J.M. de Ruijter, A.H. van Gennip, H.N. Caron, S. Kemp, and A.B.P. van Kuilenburg Histone deacetylases (HDACs): Characterization of the classical HDAC family Biochem J 370 2003 737 749
33. P. Desplats, B. Spencer, E. Coffee, P. Patel, S. Michael, and C. Patrick α-Synuclein sequesters Dnmt1 from the nucleus: A novel mechanism for epigenetic alterations in Lewy body diseases J Biol Chem 286 2011 9031 9037
34. C.L. DeVane Pharmacokinetics, drug interactions, and tolerability of valproate Psychopharmacol Bull 37 Suppl. 2 2003 25 42
35. M.J. Devine, H. Plun-Favreau, and N.W. Wood Parkinson's disease and cancer: Two wars, one front Nat Rev Cancer 11 2011 812 823
36. K.C. Dietz, and P. Casaccia HDAC inhibitors and neurodegeneration: At the edge between protection and damage Pharmacol Res 62 2010 11 17
37. J. Dragovic, S.H. Kim, S.L. Brown, and J.H. Kim Nicotinamide pharmacokinetics in patients Radiother Oncol 36 1995 225 228
38. A. Echaniz-Laguna, O. Bousiges, J.-P. Loeffler, and A.-L. Boutillier Histone deacetylase inhibitors: Therapeutic agents and research tools for deciphering motor neuron diseases Curr Med Chem 15 2008 1263 1273
39. M. Ehrlich, M.A. Gama-Sosa, L.-H. Huang, R.M. Midgett, K.C. Kuo, and R.A. McCune Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells Nucleic Acids Res 10 1982 2709 2721
40. G. Faraco, L. Cavone, and A. Chiarugi The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis Mol Med 17 2011 442 447
41. R.J. Ferrante, J.K. Kubilus, J. Lee, H. Ryu, A. Beesen, and B. Zucker Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice J Neurosci 23 2003 9418 9427
42. A. Fischer, F. Sananbenesi, A. Mungenast, and L.-H. Tsai Targeting the correct HDAC(s) to treat cognitive disorders Trends Pharmacol Sci 31 2010 605 617
43. B. Fleiss, M. Nilsson, K. Blomgren, and C. Mallard Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide- sensitised neonatal hypoxic-ischaemic brain injury J Neuroinflammation 9 2012 70
44. T. Foltynie, and M.I. Hariz Surgical management of Parkinson's disease Expert Rev Neurother 10 2010 903 914
45. H. Fujiwara, M. Hasegawa, N. Dohmae, A. Kawashima, E. Masliah, and M.S. Goldberg α-Synuclein is phosphorylated in synucleinopathy lesions Nature 4 2002 160 164
46. F.O. Fuks DNA methylation and histone modifications: Teaming up to silence genes Curr Opin Genet Dev 15 2005 490 495
47. F.O. Fuks, P.J. Hurd, D. Wolf, X. Nan, A.P. Bird, and T. Kouzarides The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation J Biol Chem 278 2003 4035 4040
48. R. Furumai, A. Matsuyama, N. Kobashi, K.-H. Lee, M. Nishiyama, and H. Nakajima FK228 (Depsipeptide) as a natural prodrug that inhibits class i histone deacetylases Cancer Res 62 2002 4916 4921
49. G. Gardian, S.E. Browne, D.-K. Choi, P. Klivenyi, J. Gregorio, and J.K. Kubilus Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease J Biol Chem 280 2005 556 563
50. G. Gardian, L. Yang, C. Cleren, N. Calingasan, P. Klivenyi, and M. Beal Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity Neuromolecular Med 5 2004 235 241
51. M.A. Glozak, N. Sengupta, X. Zhang, and E. Seto Acetylation and deacetylation of non-histone proteins Gene 363 2005 15 23
52. C.G. Goetz, and K. Kompoliti Parkinson's disease M.F. Beal, A.E. Lang, A. Ludolph, Neurodegenerative Disease 2005 Cambridge University Press Cambridge
53. M. Gottlicher, S. Minucci, P. Zhu, O.H. Kramer, A. Schimpf, and S. Giavara Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 20 2001 6969 6978
54. J. Gräff, and I.M. Mansuy Epigenetic dysregulation in cognitive disorders Eur J Neurosci 30 2009 1 8
55. J. Gräff, D. Rei, J.-S. Guan, W.-Y. Wang, J. Seo, and K.M. Hennig An epigenetic blockade of cognitive functions in the neurodegenerating brain Nature 483 2012 222 226
56. J. Gräff, and L.-H. Tsai The potential of HDAC inhibitors as cognitive enhancers Annu Rev Pharmacol Toxicol 53 2013 311 330
57. D.R. Grayson, M. Kundakovic, and R.P. Sharma Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77 2010 126 135
58. K.N. Green, J.S. Steffan, H. Martinez-Coria, X. Sun, S.S. Schreiber, and L.M. Thompson Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau J Neurosci 28 2008 11500 11510
59. I. Gregoretti, Y.-M. Lee, and H.V. Goodson Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J Mol Biol 338 2004 17 31
60. N. Gurvich, O.M. Tsygankova, J.L. Meinkoth, and P.S. Klein Histone deacetylase is a target of valproic acid-mediated cellular differentiation Cancer Res 64 2004 1079 1086
61. E. Habibi, A. Masoudi-Nejad, H. Abdolmaleky, and S. Haggarty Emerging roles of epigenetic mechanisms in Parkinson's disease Funct Integr Genomics 11 2011 523 537
62. E. Hahnen, J. Hauke, C. Tränkle, I.Y. Eyüpoglu, B. Wirth, and I. Blümcke Histone deacetylase inhibitors: possible implications for neurodegenerative disorders Expert Opin Investig Drugs 17 2008 169 184
63. M.C. Haigis, and D.A. Sinclair Mammalian sirtuins: Biological insights and disease relevance Annu Rev Pathol 5 2010 253 295
64. T. Hathorn, A. Snyder-Keller, and A. Messer Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease Neurobiol Dis 41 2011 43 50
65. M. Inden, Y. Kitamura, H. Takeuchi, T. Yanagida, K. Takata, and Y. Kobayashi Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone J Neurochem 101 2007 1491 1504
66. IPDGC, and WTCCC A two-stage meta-analysis identifies several new loci for Parkinson's disease PLoS Genet 7 2011 e1002142
67. K.A. Jellinger Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts Mov Disord 27 2012 8 30
68. M.R. Jeong, R. Hashimoto, V.V. Senatorov, K. Fujimaki, M. Ren, and M.S. Lee Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: A role of histone deacetylase inhibition FEBS Lett 542 2003 74 78
69. A. Jowaed, I. Schmitt, O. Kaut, and U. Wullner Methylation regulates alpha-synuclein expression and is decreased in parkinson's disease patients' brains J Neurosci 30 2010 6355 6359
70. S. Kaul, V. Anantharam, A. Kanthasamy, and A.G. Kanthasamy Wild-type α-synuclein interacts with pro-apoptotic proteins PKCδ and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death Mol Brain Res 139 2005 137 152
71. A.G. Kazantsev, and L.M. Thompson Therapeutic application of histone deacetylase inhibitors for central nervous system disorders Nat Rev Drug Discov 7 2008 854 868
72. N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, and N. Khramtsov Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem J 409 2008 581 589
73. S.K. Kidd, and J.S. Schneider Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition Brain Res 1354 2010 172 178
74. S.K. Kidd, and J.S. Schneider Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Neuroscience 194 2011 189 194
75. H.J. Kim, M. Rowe, M. Ren, J.-S. Hong, P.-S. Chen, and D.-M. Chuang Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: Multiple mechanisms of action J Pharmacol Exp Ther 321 2007 892 901
76. Y.S. Kim, and T.H. Joh Microglia, major player in the brain inflammation: Their roles in the pathogenesis of Parkinson's disease Exp Mol Med 38 2006 333 347
77. Z. Konsoula, and F.A. Barile Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders J Pharmacol Toxicol Methods 66 3 2012 215 220
78. E. Kontopoulos, J.D. Parvin, and M.B. Feany α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity Hum Mol Genet 15 2006 3012 3023
79. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
80. B. Langley, M.A. D'Annibale, K. Suh, I. Ayoub, A. Tolhurst, and B.L. Bastan Pulse Inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21waf1/cip1 in cell cycle-independent neuroprotection J Neurosci 28 2008 163 176
81. E.C. Lauterbach, and M.F. Mendez Psychopharmacological neuroprotection in neurodegenerative diseases, Part III: Criteria-based assessment: A report of the ANPA committee on research J Neuropsychiatry Clin Neurosci 23 2011 242 260
82. M.W. Lawless, S. Norris, K.J. O'Byrne, and S.G. Gray Targeting histone deacetylases for the treatment of disease J Cell Mol Med 13 2009 826 852
83. J.Y. Lee, H.S. Kim, H.Y. Choi, T.H. Oh, B.G. Ju, and T.Y. Yune Valproic acid attenuates blood-spinal cord barrier disruption by inhibiting matrix metalloprotease-9 activity and improves functional recovery after spinal cord injury J Neurochem 121 2012 818 829
84. M.G. Lee, C. Wynder, D.M. Schmidt, D.G. McCafferty, and R. Shiekhattar Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications Chem Biol 13 2006 563 567
85. V.M.Y. Lee, and J.Q. Trojanowski Mechanisms of Parkinson's disease linked to pathological α-synuclein: New targets for drug discovery Neuron 52 2006 33 38
86. Y. Leng, and D.-M. Chuang Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity J Neurosci 26 2006 7502 7512
87. N. Lev, D. Roncevich, D. Ickowicz, E. Melamed, and D. Offen Role of DJ-1 in Parkinson's disease J Mol Neurosci 29 2006 215 225
88. J.M. Levenson, K.J. O'Riordan, K.D. Brown, M.A. Trinh, D.L. Molfese, and J.D. Sweatt Regulation of histone acetylation during memory formation in the hippocampus J Biol Chem 279 2004 40545 40559
89. F. Li, T. Macfarlan, R.N. Pittman, and D. Chakravarti Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities J Biol Chem 277 2002 45004 45012
90. D. Liu, R. Gharavi, M. Pitta, M. Gleichmann, and M. Mattson Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons Neuromolecular Med 11 2009 28 42
91. W. Löscher Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy CNS Drugs 16 2002 669 694
92. Q. Lu, Y.-T. Yang, C.-S. Chen, M. Davis, J.C. Byrd, and M.R. Etherton Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors J Med Chem 47 2003 467 474
93. N.E. Maestri, S.W. Brusilow, D.B. Clissold, and S.S. Bassett Long-term treatment of girls with ornithine transcarbamylase deficiency N Engl J Med 335 1996 855 860
94. K. Maiese, and Z.Z. Chong Nicotinamide: Necessary nutrient emerges as a novel cytoprotectant for the brain Trends Pharmacol Sci 24 2003 228 232
95. B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 2007 1247 1252
96. Z. Marinova, M. Ren, J.R. Wendland, Y. Leng, M.-H. Liang, and S. Yasuda Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: A potential role of Sp1 acetylation J Neurochem 111 2009 976 987
97. P.A. Marks, V.M. Richon, R. Breslow, and R.A. Rifkind Histone deacetylase inhibitors as new cancer drugs Curr Opin Oncol 13 2001 477 483
98. P.A. Marks, V.M. Richon, T. Miller, and W.K. Kelly Histone deacetylase inhibitors Advances in Cancer Research Vol. 91 2004 Academic Press 137 168
99. P.A. Marks, R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, and W.K. Kelly Histone deacetylases and cancer: Causes and therapies Nat Rev Cancer 1 2001 194 202
100. S.C.F. Marques, C.R. Oliveira, C.M.F. Pereira, and T.F. Outeiro Epigenetics in neurodegeneration: A new layer of complexity Prog Neuropsychopharmacol Biol Psychiatry 35 2011 348 355
101. L. Matsumoto, H. Takuma, A. Tamaoka, H. Kurisaki, H. Date, and S. Tsuji CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease PLoS One 5 2010 e15522
102. I. Maze, K.-M. Noh, and C.D. Allis Histone regulation in the CNS: Basic principles of epigenetic plasticity Neuropsychopharmacology 38 1 2012 3 22
103. K.S.P. McNaught, L.M. Bjorklund, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Proteasome inhibition causes nigral degeneration with inclusion bodies in rats Neuroreport 13 11 2002 1437 1441
104. M.J. Meaney Epigenetics and the biological definition of gene × environment interactions Child Dev 81 2010 41 79
105. A. Meisel, C. Harms, F. Yildirim, J. Bösel, G. Kronenberg, and U. Harms Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation J Neurochem 98 2006 1019 1031
106. L. Migliore, and F. Coppedè Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases Mutat Res Fundam Mol Mech Mutagen 667 2009 82 97
107. S. Mimasu, T. Sengoku, S. Fukuzawa, T. Umehara, and S. Yokoyama Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A Biochem Biophys Res Commun 366 2008 15 22
108. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 2006 38 51
109. T.B. Miranda, and P.A. Jones DNA methylation: The nuts and bolts of repression J Cell Physiol 213 2007 384 390
110. T. Mokudai, I.A. Ayoub, Y. Sakakibara, E.-J. Lee, C.S. Ogilvy, and K.I. Maynard Delayed treatment with nicotinamide (vitamin B3) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in wistar rats Stroke 31 2000 1679 1685
111. B. Monti, V. Gatta, F. Piretti, S. Raffaelli, M. Virgili, and A. Contestabile Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: Involvement of α-synuclein Neurotox Res 17 2010 130 141
112. B. Monti, D. Mercatelli, and A. Contestabile Valproic acid neuroprotection in 6-OHDA lesioned rat, a model for Parkinson's disease HOAJ Biol 1 2012 1 4
113. B. Monti, E. Polazzi, L. Batti, C. Crochemore, M. Virgili, and A. Contestabile Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death J Neurochem 103 2007 518 530
114. B. Monti, E. Polazzi, and A. Contestabile Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection Curr Mol Pharmacol 2 2009 95 109
115. D.J. Moore, A.B. West, V.L. Dawson, and T.M. Dawson Molecular pathophysiology of Parkinson's disease Annu Rev Neurosci 28 2005 57 87
116. L.D. Moore, T. Le, and G. Fan DNA methylation and its basic function Neuropsychopharmacology 38 1 2012 23 38
117. R.I. Morimoto, and M.G. Santoro Stress-inducible responses and heat shock proteins: New pharmacologic targets for cytoprotection Nat Biotechnol 16 1998 833 838
118. B. Morrison, N. Majdzadeh, and S. D'Mello Histone deacetylases: Focus on the nervous system Cell Mol Life Sci 64 2007 2258 2269
119. H. Nakajima, Y.B. Kim, H. Terano, M. Yoshida, and S. Horinouchi FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor Exp Cell Res 241 1998 126 133
120. A.P. Nicholas, F.D. Lubin, P.J. Hallett, P. Vattem, P. Ravenscroft, and E. Bezard Striatal histone modifications in models of levodopa-induced dyskinesia J Neurochem 106 2008 486 494
121. E.H. Norris, B.I. Giasson, V.M.Y. Lee, and P.S. Gerald α-Synuclein: Normal function and role in neurodegenerative diseases Current Topics in Developmental Biology Vol. 60 2004 Academic Press 17 54
122. J. Nutt, A. Williams, C. Plotkin, N. Eng, M. Ziegler, and D.B. Calne Treatment of Parkinson's disease with sodium valproate: Clinical, pharmacological, and biochemical observations Can J Neurol Sci 6 1979 337 343
123. K. Ono, M. Ikemoto, T. Kawarabayashi, M. Ikeda, T. Nishinakagawa, and M. Hosokawa A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice Parkinsonism Relat Disord 15 2009 649 654
124. T.F. Outeiro, E. Kontopoulos, S.M. Altmann, I. Kufareva, K.E. Strathearn, and A.M. Amore Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease Science 317 2007 516 519
125. T.F. Outeiro, O. Marques, and A. Kazantsev Therapeutic role of sirtuins in neurodegenerative disease Biochim Biophys Acta Mol Basis Dis 1782 6 2008 363 369
126. J. Pagonabarraga, and J. Kulisevsky Cognitive impairment and dementia in Parkinson's disease Neurobiol Dis 46 2012 590 596
127. T. Pan, X. Li, W. Xie, J. Jankovic, and W. Le Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells FEBS Lett 579 2005 6716 6720
128. G.-S. Peng, G. Li, N.-S. Tzeng, P.-S. Chen, D.-M. Chuang, and Y.-D. Hsu Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: Role of microglia Mol Brain Res 134 2005 162 169
129. E. Perucca Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience CNS Drugs 16 2002 695 714
130. S. Petri, M. Kiaei, K. Kipiani, J. Chen, N.Y. Calingasan, and J.P. Crow Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis Neurobiol Dis 22 2006 40 49
131. C.J. Phiel, F. Zhang, E.Y. Huang, M.G. Guenther, M.A. Lazar, and P.S. Klein Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 276 2001 36734 36741
132. L. Pirkkala, P. Nykanen, and L. Sistonen Roles of the heat shock transcription factors in regulation of the heat shock response and beyond FASEB J 15 2001 1118 1131
133. J.A. Plumb, P.W. Finn, R.J. Williams, M.J. Bandara, M.R. Romero, and C.J. Watkins Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 Mol Cancer Ther 2 2003 721 728
134. W. Poewe, A. Antonini, J.C.M. Zijlmans, P.R. Burkhard, and F. Vigerhoets Levodopa in the treatment of Parkinson's disease: An old drug still going strong Clin Interv Aging 5 2010 229 238
135. A. Portela, and M. Esteller Epigenetic modifications and human disease Nat Biotechnol 28 2010 1057 1068
136. R. Prediger, A.J. Aguiar, E. Moreira, F. Matheus, A. Castro, and R. Walz The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A new rodent model to test palliative and neuroprotective agents for Parkinson's disease Curr Pharm Des 17 2011 489 507
137. P.A. Price, J.D. Parkes, and C.D. Marsden Sodium valproate in the treatment of levodopa-induced dyskinesia J Neurol Neurosurg Psychiatry 41 1978 702 706
138. S. Przedborski, V. Jackson-Lewis, R. Djaldetti, G. Liberatore, M. Vila, and S. Vukosavic The parkinsonian toxin MPTP: Action and mechanism Restor Neurol Neurosci 16 2000 135 142
139. X. Qi, T. Hosoi, Y. Okuma, M. Kaneko, and Y. Nomura Sodium 4-phenylbutyrate protects against cerebral ischemic injury Mol Pharmacol 66 2004 899 908
140. S.S. Ramalingam, S. Kummar, J. Sarantopoulos, S. Shibata, P. LoRusso, and M. Yerk J Clin Oncol 28 29 2010 4507 4512
141. P. Rane, J. Shields, M. Heffernan, Y. Guo, S. Akbarian, and J.A. King The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD Neuropharmacology 62 2012 2409 2412
142. S.Y. Roth, J.M. Denu, and C.D. Allis Histone acetyltransferases Annu Rev Biochem 70 2001 81 120
143. A. Rottach, H. Leonhardt, and F. Spada DNA methylation-mediated epigenetic control J Cell Biochem 108 2009 43 51
144. C. Rouaux, N. Jokic, C. Mbebi, S. Boutillier, J.-P. Loeffler, and A.-L. Boutillier Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration EMBO J 22 2003 6537 6549
145. A. Roy, A. Ghosh, A. Jana, X. Liu, S. Brahmachari, and H.E. Gendelman Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease PLoS One 7 2012 e38113
146. H. Ryu, J. Lee, B.A. Olofsson, A. Mwidau, A. Deodoglu, and M. Escudero Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway Proc Natl Acad Sci 100 2003 4281 4286
147. G. Sadri-Vakili, and J.-H.J. Cha Histone deacetylase inhibitors: A novel therapeutic approach to huntington's disease (complex mechanism of neuronal death) Curr Alzheimer Res 3 2006 403 408
148. R.N. Saha, and K. Pahan HATs and HDACs in neurodegeneration: A tale of disconcerted acetylation homeostasis Cell Death Differ 13 2006 539 550
149. A. Salminen, T. Tapiola, P. Korhonen, and T. Suuronen Neuronal apoptosis induced by histone deacetylase inhibitors Mol Brain Res 61 1998 203 206
150. L. Sanderson, G.W. Taylor, E.O. Aboagye, J.P. Alao, J.R. Latigo, and R.C. Coombes Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice Drug Metab Dispos 32 10 2004 1132 1138
151. L.R. Saunders, and E. Verdin Sirtuins: Critical regulators at the crossroads between cancer and aging Oncogene 26 2007 5489 5504
152. S. Schmalbach, and S. Petri Histone deacetylation and motor neuron degeneration CNS Neurol Disord Drug Targets 9 2010 279 284
153. D.M.Z. Schmidt, and D.G. McCafferty Trans-2-phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1†Biochemistry 46 2007 4408 4416
154. M.D. Shahbazian, and M. Grunstein Functions of site-specific histone acetylation and deacetylation Annu Rev Biochem 76 2007 75 100
155. T.B. Sherer, J.-H. Kim, R. Betarbet, and J.T. Greenamyre Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation Exp Neurol 179 2003 9 16
156. Y. Shi, F. Lan, C. Matson, P. Mulligan, J.R. Whetstine, and P.A. Cole Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 Cell 119 2004 941 953
157. B. Shin, J.R. Bulitta, J. Balthasar, M. Kim, Y. Choi, and S. Yoo Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling Cancer Chemother Pharmacol 68 2011 465 475
158. Song-Hee Yu, D.-C. Cho, K.-T. Kim, K.-H. Nam, H.-J. Cho, and J.-K. Sung The neuroprotective effect of treatment of valproic acid in acute spinal cord injury J Korean Neurosurg Soc 51 2012 191 198
159. S. Spange, T. Wagner, T. Heinzel, and O.H. Krämer Acetylation of non-histone proteins modulates cellular signalling at multiple levels Int J Biochem Cell Biol 41 2009 185 198
160. M.G. Spillantini, M.L. Schmidt, V.M.-Y. Lee, J.Q. Trojanowski, R. Jakes, and M. AU - Goedert α-Synuclein in Lewy bodies Nature 388 1997 839 840
161. H.S. Suh, S. Choi, P. Khattar, N. Choi, and S.C. Lee Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes J Neuroimmune Pharmacol 5 2010 521 532
162. P. Svenningsson, E. Westman, C. Ballard, and D. Aarsland Cognitive impairment in patients with Parkinson's disease: Diagnosis, biomarkers, and treatment Lancet Neurol 11 2012 697 707
163. M. Tanaka, Y.M. Kim, G. Lee, E. Junn, T. Iwatsubo, and M.M. Mouradian Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective J Biol Chem 279 2004 4625 4631
164. B. Thomas, and M.F. Beal Parkinson's disease Hum Mol Genet 16 2007 R183 R194
165. J. Trapp, R. Meier, D. Hongwiset, M.U. Kassack, W. Sippl, and M. Jung Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins) ChemMedChem 2 2007 1419 1431
166. N. Tsuji, M. Kobayashi, K. Nagashima, Y. Wakisaka, and K. Koizumi A new antifungal antibiotic, trichostatin J Antibiot 29 1 1976 1 6
167. Y.-I. Tsukada, J. Fang, H. Erdjument-Bromage, M.E. Warren, C.H. Borchers, and P. Tempst Histone demethylation by a family of JmjC domain-containing proteins Nature 439 2006 811 816
168. F.J.E. Vajda Valproate and neuroprotection J Clin Neurosci 9 2002 508 514
169. K.M. VanderMolen, W. McCulloch, C.J. Pearce, and N.H. Oberlies Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma J Antibiot 64 2011 525
170. A. Villar-Garea, and M. Esteller Histone deacetylase inhibitors: Understanding a new wave of anticancer agents Int J Cancer 112 2004 171 178
171. J.M. Wagner, B. Hackanson, M. Lübbert, and M. Jung Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy Clin Epigenetics 1 3-4 2010 117 136
172. B. Wang, X. Zhu, Y. Kim, J. Li, S. Huang, and S. Saleem Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage Free Radic Biol Med 52 2012 928 936
173. Y. Wang, X. Wang, L. Liu, and X. Wang HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells Neurosci Lett 467 2009 212 216
174. J.C. Wiley, C. Pettan-Brewer, and W.C. Ladiges Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice Aging Cell 10 2011 418 428
175. J.Y. Wu, F.N. Niu, R. Huang, and Y. Xu Enhancement of glutamate uptake in 1-methyl-4-phenylpyridinium-treated astrocytes by trichostatin A Neuroreport 19 2008 1209 1212
176. X. Wu, P.S. Chen, S. Dallas, B. Wilson, M.L. Block, and C.-C. Wang Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons Int J Neuropsychopharmacol 11 2008 1123 1134
177. J.C.M. Ximenes, E.C.L. Verde, M.D.G. Naffah-Mazzacoratti, and G.S.D.B. Viana Valproic acid, a drug with multiple molecular targets related to its potential neuroprotective action Neurosci Med 3 2012 107 123
178. K. Xu, X.L. Dai, H.C. Huang, and Z.F. Jiang Targeting HDACs: A promising therapy for Alzheimer's disease Oxidative Med Cell Longev 2011 (Epub ahead of print)
179. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552
180. A. Xuan, D. Long, J. Li, W. Ji, L. Hong, and M. Zhang Neuroprotective
181. M. Yoshida, M. Kijima, M. Akita, and T. Beppu Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A J Biol Chem 265 1990 17174 17179
182. Y. Zhang, N. Li, C. Caron, G. Matthias, D. Hess, and S. Khochbin HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo EMBO J 22 2003 1168 1179
183. W. Zhou, K. Bercury, J. Cummiskey, N. Luong, J. Lebin, and C.R. Freed Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease J Biol Chem 286 2011 14941 14951